TY - JOUR
T1 - Convalescent plasma treatment of severe COVID-19
T2 - a propensity score–matched control study
AU - Liu, Sean T.H.
AU - Lin, Hung Mo
AU - Baine, Ian
AU - Wajnberg, Ania
AU - Gumprecht, Jeffrey P.
AU - Rahman, Farah
AU - Rodriguez, Denise
AU - Tandon, Pranai
AU - Bassily-Marcus, Adel
AU - Bander, Jeffrey
AU - Sanky, Charles
AU - Dupper, Amy
AU - Zheng, Allen
AU - Nguyen, Freddy T.
AU - Amanat, Fatima
AU - Stadlbauer, Daniel
AU - Altman, Deena R.
AU - Chen, Benjamin K.
AU - Krammer, Florian
AU - Mendu, Damodara Rao
AU - Firpo-Betancourt, Adolfo
AU - Levin, Matthew A.
AU - Bagiella, Emilia
AU - Casadevall, Arturo
AU - Cordon-Cardo, Carlos
AU - Jhang, Jeffrey S.
AU - Arinsburg, Suzanne A.
AU - Reich, David L.
AU - Aberg, Judith A.
AU - Bouvier, Nicole M.
N1 - Funding Information:
This study was supported by internal funding from MSH and ISMMS. We thank all of the patients who participated in this study and their families. We also acknowledge the generosity of the thousands of anonymous tristate area residents who recovered from COVID-19 and then volunteered to donate convalescent plasma for the benefit of others. We thank the New York Blood Center, L.-A. Pirofski, T. Schneider, C. Seah, S. Srinivas, D. Tremblay, M. Geiger, C. Lebovits and J. Lustgarten. We acknowledge the assistance of ISMMS medical students: S. Ahsanuddin, A. Paasewe, R. Upadhyay, G. Mellgard, T. Martinson, B. Patil, C. Luo, S. Agrawal, A. Siddiqui, J. Schwarz, L. Piendel, J. Emerson, H. Kaplan, E. Klein, M. Garcia, J. Johnson, L. Maillie and E. Baldwin. We also appreciate the clinical expertise of the Mount Sinai Convalescent Plasma Squad: N. Shuman, D. Delbeau, D. Catamero, G. Sanchez, S. Aird, M. Mann, T. Broome, S. Kleiner-Arje, L. Wolf, A. Lee, L. Gaynes and K. Goodman. We dedicate this work to the New Yorkers who have lost their lives to COVID-19 with a special dedication to the health care workers who will always be remembered for their selflessness during this pandemic.
Publisher Copyright:
© 2020, The Author(s), under exclusive licence to Springer Nature America, Inc.
PY - 2020/11
Y1 - 2020/11
N2 - Coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), is a new human disease with few effective treatments1. Convalescent plasma, donated by persons who have recovered from COVID-19, is the acellular component of blood that contains antibodies, including those that specifically recognize SARS-CoV-2. These antibodies, when transfused into patients infected with SARS-CoV-2, are thought to exert an antiviral effect, suppressing virus replication before patients have mounted their own humoral immune responses2,3. Virus-specific antibodies from recovered persons are often the first available therapy for an emerging infectious disease, a stopgap treatment while new antivirals and vaccines are being developed1,2. This retrospective, propensity score–matched case–control study assessed the effectiveness of convalescent plasma therapy in 39 patients with severe or life-threatening COVID-19 at The Mount Sinai Hospital in New York City. Oxygen requirements on day 14 after transfusion worsened in 17.9% of plasma recipients versus 28.2% of propensity score–matched controls who were hospitalized with COVID-19 (adjusted odds ratio (OR), 0.86; 95% confidence interval (CI), 0.75–0.98; chi-square test P value = 0.025). Survival also improved in plasma recipients (adjusted hazard ratio (HR), 0.34; 95% CI, 0.13–0.89; chi-square test P = 0.027). Convalescent plasma is potentially effective against COVID-19, but adequately powered, randomized controlled trials are needed.
AB - Coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), is a new human disease with few effective treatments1. Convalescent plasma, donated by persons who have recovered from COVID-19, is the acellular component of blood that contains antibodies, including those that specifically recognize SARS-CoV-2. These antibodies, when transfused into patients infected with SARS-CoV-2, are thought to exert an antiviral effect, suppressing virus replication before patients have mounted their own humoral immune responses2,3. Virus-specific antibodies from recovered persons are often the first available therapy for an emerging infectious disease, a stopgap treatment while new antivirals and vaccines are being developed1,2. This retrospective, propensity score–matched case–control study assessed the effectiveness of convalescent plasma therapy in 39 patients with severe or life-threatening COVID-19 at The Mount Sinai Hospital in New York City. Oxygen requirements on day 14 after transfusion worsened in 17.9% of plasma recipients versus 28.2% of propensity score–matched controls who were hospitalized with COVID-19 (adjusted odds ratio (OR), 0.86; 95% confidence interval (CI), 0.75–0.98; chi-square test P value = 0.025). Survival also improved in plasma recipients (adjusted hazard ratio (HR), 0.34; 95% CI, 0.13–0.89; chi-square test P = 0.027). Convalescent plasma is potentially effective against COVID-19, but adequately powered, randomized controlled trials are needed.
UR - http://www.scopus.com/inward/record.url?scp=85091021220&partnerID=8YFLogxK
U2 - 10.1038/s41591-020-1088-9
DO - 10.1038/s41591-020-1088-9
M3 - Article
C2 - 32934372
AN - SCOPUS:85091021220
SN - 1078-8956
VL - 26
SP - 1708
EP - 1713
JO - Nature Medicine
JF - Nature Medicine
IS - 11
ER -